Bicycle Therapeutics (BCYC) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Bicycle Therapeutics (BCYC) overview

Bicycle Therapeutics (BCYC) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 72.6m and operating profit of USD -247m; the year-end share price was 7.08 USD and market capitalisation was USD 491m. Bicycle Therapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Bicycle Therapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 610mFY 2025
Share price7.08 USDFY 2025 year end
RevenueUSD 72.6mFY 2025
Operating profitUSD -247mFY 2025
Net earningsUSD -219mFY 2025
Market capitalisationUSD 491mFY 2025 year end

About Bicycle Therapeutics

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing synthetic peptide medicines called Bicycle molecules for diseases underserved by existing treatments. Its internal programs focus on oncology and include drug conjugates, radioconjugates, and imaging agents designed to target cancer-related molecules. The company uses a proprietary phage display platform for discovery and develops candidates through clinical studies and research collaborations.

Generate the Bicycle Therapeutics report

Bicycle Therapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Bicycle Therapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Bicycle Therapeutics

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.